BioVie Inc. (BIVI) stock
Close on Nov 13, 2026Market cap $8.52MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $8.52M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.31
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$22.59M
- EPS, diluted
- -$2.86
- Book value per share
- $0.79
- Diluted shares
- 8M
Trading
- Previous close
- $1.19
- Open
- $1.19
- Day's range
- $1.13 – $1.23
- Volume
- 217,983
- Average volume (20 days)
- 895,191
- Beta (5 years)
- 0.95
- 52-week range
- $0.82 – $3.79
- RSI (14 days)
- 40.7
- Volatility (1 year)
- 124.4%
- Relative volume
- 0.06×
- WACC
- 9.9%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | BIVI | S&P 500 | Difference | BIVI per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -5.8% | -3.0% | −2.8 pts | ||
| 3 months | -27.6% | -2.8% | −24.8 pts | ||
| Year to date | -2.6% | +11.5% | −14.1 pts | ||
| 1 year | -24.2% | +13.5% | −37.6 pts | ||
| 3 years | -99.6% | +77.7% | −177.3 pts | -84.7% | +21.1% |
| 5 years | -99.8% | +72.6% | −172.4 pts | -71.7% | +11.5% |
| 10 years | -100.0% | +308.2% | −408.2 pts | -71.0% | +15.1% |
Fourteen years at a glance
Fiscal years 2013 to 2026 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Press releases
Releases BioVie filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- Update
About BioVie
Pharmaceutical Preparations
BioVie Inc. is a clinical-stage biopharmaceutical company that develops drug therapies for neurological and neurodegenerative disorders as well as advanced liver disease. Its neurodegenerative pipeline centers on bezisterim (NE3107), an investigational, orally administered small molecule designed to inhibit neuroinflammation and insulin resistance in conditions such as Parkinson’s disease, Alzheimer’s disease, and long COVID. In liver disease, the company develops BIV201, a continuous infusion liquid formulation of terlipressin targeting ascites and complications of liver cirrhosis. Because its therapeutic candidates remain under clinical investigation, the company does not have commercial products or regular commercial customers.
Company profile, executives and historyBioVie stock: common questions
What is BioVie's stock price?
BIVI closed at $1.13 on Nov 13, 2026, down 5.04% on the day. Over the past 52 weeks it traded between $0.82 and $3.79.
What is BioVie's market cap?
BioVie was worth $8.52M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is BIVI's P/E ratio?
BioVie lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.86), so it has no meaningful P/E ratio.
Does BioVie pay a dividend?
No. BioVie has not paid a cash dividend over the last twelve months.
How has BIVI stock performed over the past year?
Including dividends, BIVI returned -24.2% over the past year, against +13.5% for the S&P 500.
Who are BioVie's competitors?
Companies most similar to BioVie by business, industry and size include ANVS, OGEN, ALZN, BHVN, ANNX.
See a number that looks wrong?